(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

PURPOSE: (188)Re-HEDP is indicated for the treatment of pain in patients with painful osteoblastic bone metastases, including hormone-refractory prostate cancer patients. Efficacy may be improved by adding chemotherapy to the treatment regimen as a radiation sensitizer. The combination of (188)Re-HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Marnix G. E. H., Bosma, Tjitske B., van Rijk, Peter P., Zonnenberg, Bernard A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724641/
https://www.ncbi.nlm.nih.gov/pubmed/19319526
http://dx.doi.org/10.1007/s00259-009-1119-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724641/
https://www.ncbi.nlm.nih.gov/pubmed/19319526
http://dx.doi.org/10.1007/s00259-009-1119-8

Ejemplares similares